Ekaterina Manuylova
Endocrinology, Diabetes & Metabolism · Salem, ORNPI 1831459817
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,613 of the $2,313 with a category attached, or 69.7%. 23 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 30.3% of the total.
Across 66 payments — averaging $35.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$700
- Amgen$680
- Medtronic$162
- Novo Nordisk$160
- GSK$95
- Madrigal Pharmaceuticals$62
- plus $455 from 17 others
What the payments were for
- Speaking & faculty fees$70030%
- Food & beverage$1,61370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 2 | $700 |
| Amgen | 27 | $680 |
| Medtronic(2 entities) | 4 | $162 |
| Novo Nordisk | 4 | $160 |
| GSK | 5 | $95 |
| Madrigal Pharmaceuticals | 2 | $62 |
| Boehringer Ingelheim | 2 | $55 |
| Exact Sciences | 2 | $43 |
| Astellas Pharma US Inc | 2 | $38 |
| Johnson & Johnson | 2 | $33 |
| Echosens North America, Inc. | 1 | $29 |
| Dexcom, Inc. | 2 | $28 |
| Lilly USA, LLC | 1 | $26 |
| Corcept Therapeutics | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Pfizer | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $21 |
| Mannkind Corporation | 1 | $18 |
| Bayer | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Abbott | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$700
- EVENITY$125
- MINIMED 780G$106
How this compares
$2,313 in reported general payments places this provider in the 65th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 149 | $251,571 |
| JardianceEmpagliflozin | 83 | $128,051 |
| Somatuline DepotLanreotide Acetate | 12 | $108,061 |
| TrulicityDulaglutide | 39 | $56,254 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $45,971 |
| MounjaroTirzepatide | 32 | $45,025 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $41,641 |
| Teriparatide | 14 | $36,687 |
| SomavertPegvisomant | 11 | $30,115 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $24,686 |
| ProliaDenosumab | 14 | $23,739 |
| FarxigaDapagliflozin Propanediol | 21 | $23,609 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $18,701 |
| Novolog FlexpenInsulin Aspart | 34 | $17,544 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 23 | $15,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $160 | $251,571149 claims |
| Boehringer IngelheimJardiance | $55 | $128,05183 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $26 | $110,62199 claims |
| PfizerSomavert | $23 | $30,11511 claims |
| AmgenProlia | $680 | $23,73914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
Other endocrinology, diabetes & metabolism in Salem
- Rodney MichaelsSalem$2K
- Thomas ChamberlinSalem$137
- Michael McClungPortland$1.3M
- Maria FleseriuPortland$464K
- James NeifingPortland$311K
- Rodica BusuiPortland$255K
- Jonathan PurnellPortland$212K
- Patricia HopsonCorvallis$166K
- Eric OrwollPortland$94K
- Paul DuellPortland$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.